SNDX · Syndax Pharmaceuticals, Inc.
AI read · Neutral
The AI's read
An analyst's view can shape how investors see Syndax, but this report gives no new information about its medicines or business plans. The lower target and retained Buy rating point in different directions, so neither supports a clear change in the company's outlook.